Allakos — Corporate Update (March 2020)
40 slides from Allakos's corporate update, Mar 24, 2020
Slide 1: Corporate Update March 2020
Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Corporate Update March 2020 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b
Slide 3: Agenda
Agenda Robert Alexander, PhD Overview 5:00 – 5:20 PM Henrik Rasmussen, MD PhD Initiated clinical studies MGID Phase 1 study results 5:20 – 5:50 PM Q&A 5:50 – 6:00 PM
Slide 4: Overview
Overview Robert Alexander, PhD CEO – Allakos
Slide 5: Executive Summary
Executive Summary Recently initiated Phase 3 study in Eosinophilic Gastritis (EG) and/or Eosinophilic Duodenitis (EoD; previously referred to as EGE) Recently initiated Phase 2/3 study in Eosinophilic Esophagitis (EoE) First group of subjects dosed in Phase 1 subcutaneous healthy volunteer study Pos
Slide 6: Impact of Coronavirus on Allakos Clinical Trials
Impact of Coronavirus on Allakos Clinical Trials Phase 3 EG/EoD and Phase 2/3 EoE sites have been activated and potential patients have been identified To avoid study disruption, we have decided to delay enrollment in the Phase 3 EG/EoD and the Phase 2/3 EoE studies Current estimated completion of H
Slide 7: Antolimab (AK002) Targets Siglec-8 on Mast Cells and Eosinophils
Antolimab (AK002) Targets Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response Antolimab Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis Antolimab
Slide 8: Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease
Mast Cells and Eosinophils Are Key Drivers of Inflammatory Disease
Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases
Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Duodenitis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTESTINAL
Slide 10: Eosinophilic Gastrointestinal Diseases (EGIDs)
Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Duodenitis (EoD) = US Prevalence ~20-25K ~25K ~200K EG, EoD, EoE Chronic Eosinophilic Inflammation of the Stomach, Duodenum, or Esophagus Eosinophils and
Slide 11: EGID Biopsies Have Elevated Eosinophils & Mast Cells
EGID Biopsies Have Elevated Eosinophils & Mast Cells Source: Youngblood B, et al. JCI Insights. 2019 Eosinophils 10 8 6 4 2 0 Mast Cells 15 10 5 0 Mast Cells 12 8 4 0 Eosinophils 12 8 4 0 % of CD45+ Viable Cells Esophagus Stomach Normal EoE Normal EoE Normal EG Normal EG *p<0.05
Slide 12: Eos and Mast Cells Are Activated in EGID Biopsies
Eos and Mast Cells Are Activated in EGID Biopsies CD63 3000 2000 1000 0 150000 100000 50000 0 IgE 8000 4000 2000 0 6000 CD49d 60000 40000 20000 0 CD11b Eosinophils Mast Cells Normal EG Normal EG Normal EG Normal EG Source: Youngblood B, et al. JCI Insights. 2019 *p<0.05 Eosinophils and mast cells bo
Slide 13: End of Phase 2 (ENIGMA) Meeting Summary
End of Phase 2 (ENIGMA) Meeting Summary
Slide 14: Key Takeaways
Key Takeaways Histologic Co-Primary Endpoint Consistent with EoE guidance, FDA recommended using a responder analysis Histologic response thresholds set at ≤4 eos/hpf in the stomach and/or ≤15 eos/hpf in the duodenum Symptom Co-Primary Endpoint The same PRO questionnaire will be used in Phase 3 as w
Slide 15: Phase 3 EG/EoD Study Design
Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formally referred to as EGE) Study Design Henrik S. Rasmussen, MD PhD Chief Medical Officer – Allakos
Slide 16: Phase 3 Eosinophilic Gastritis and/or Duodenitis Study
Phase 3 Eosinophilic Gastritis (EG) and/or Duodenitis (EoD) Study Study Design Multi-center, randomized, double-blind, placebo-controlled study in EG/EoD Adult patients with active moderate to severe symptoms Biopsy confirmed EG/EoD Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs, and/or Duodenu
Slide 17: Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA
Symptoms Assessed With the Same PRO Questionnaire Used in ENIGMA Abdominal pain Nausea Early satiety Vomiting Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the symptoms of EG/EoD patients on a daily basis Measures symptoms
Slide 18: Phase 3 EG/EoD Endpoints
Phase 3 EG/EoD Endpoints Histologic Co-Primary Endpoint Proportion of responders: Stomach: ≤4 eos/hpf in 5 hpfs, and/or Duodenum: ≤15 eos/hpf in 3 hpfs Symptom Co-Primary Endpoint Absolute change in patient reported TSS-6 Key Secondary Endpoints Percent change in tissue eosinophils Treatment respond
Slide 19: Phase 2 ENIGMA Results Analyzed Against Phase 3 Endpoints (ITT)
Phase 2 ENIGMA Results Analyzed Against Phase 3 Endpoints (ITT) Co-Primary Endpoints Antolimab Placebo p – value 3 mg/kg Histologic Endpoint1 Proportion of Responders 95% 0% <0.0001 Symptom Endpoint2 Mean Absolute Change in TSS-6 -16.6 -8.1 0.0162 Mean Percent Change in TSS-6 -59% -27% 0.0033 1Respo
Slide 20: Phase 2/3 Eosinophilic Esophagitis (EoE) Study Design
Phase 2/3 Eosinophilic Esophagitis (EoE) Study Design
Slide 21: Phase 2/3 Eosinophilic Esophagitis (EoE) Study
Phase 2/3 Eosinophilic Esophagitis (EoE) Study Study Design Multi-center, randomized, double-blind, placebo-controlled study in Eosinophilic Esophagitis Patients (12 to 80 years old) with active moderate to severe symptoms Biopsy confirmed EoE Esophagus: ≥15 eos in 1 hpf 300 Patients – 3 arms 100 pa
Slide 22: Phase 2/3 Eosinophilic Esophagitis Endpoints
Phase 2/3 Eosinophilic Esophagitis Endpoints Histologic Co-Primary Endpoint Proportion of responders: ≤6 eos/hpf in 1 hpf in the esophagus Symptom Co-Primary Endpoint Absolute change in patient reported Dysphagia Symptom Questionnaire (DSQ) Key Secondary Endpoints Percent change in esophageal tissue
Slide 23: Phase 1 Subcutaneous Healthy Volunteer Study
Phase 1 Subcutaneous Healthy Volunteer Study
Slide 24: Phase 1 Subcutaneous Healthy Volunteer Study
Phase 1 Subcutaneous Healthy Volunteer Study Study Design Phase 1 single-dose, placebo-controlled study 50 healthy volunteers Doses assessed: SC: Antolimab 0.3, 1.0, 3.0, 5.0 mg/kg and placebo IV: Antolimab 1.0, 3.0 mg/kg Data available: Q4 2020
Slide 25: Mast Cell Gastrointestinal Disease (MGID)
Mast Cell Gastrointestinal Disease (MGID) Patients with Chronic GI Symptoms and Elevated Mast Cells
Slide 26: ENIGMA Screening Patient Distribution
ENIGMA Screening Patient Distribution Met Symptom Criteria n=88 Entered Screening n=113 16 of 88 symptomatic patients had elevated mast cells only EG / EoD n=72 Mast Cell GI Disease n=16 MGID: ≥30 Mast Cells EG/EoD: ≥30 Eos & Mast Cells1 165 met all enrollment criteria for ENIGMA; 1 patient had elev
Slide 27: Phase 1 Mast Cell GI Disease (MGID) Study
Phase 1 Mast Cell GI Disease (MGID) Study Study Design Multi-center, open-label, multi-dose, Phase 1 study Active moderate to severe symptoms as measured by PRO used in ENIGMA N=7 patients Biopsy confirmed elevated mast cells Stomach: ≥30 mast cells/high powered field (hpf) in 5 hpfs, and/or Duodenu
Slide 28: Baseline Gastrointestinal Eosinophils and Mast Cell Counts
Baseline Gastrointestinal Eosinophils and Mast Cell Counts Mean Gastrointestinal Cells Eosinophils Mast Cells Mean Gastrointestinal Cells Eosinophils Mast Cells ENIGMA EG / EoD (n=65) MGID (n=7)
Slide 29: EG/EoD and MGID Patients Have Similar Symptomatic Burden
EG/EoD and MGID Patients Have Similar Symptomatic Burden Symptom Reported Symptom Intensity During Screening (0-10) Mean Early Satiety Bloating Abdominal Pain Abdominal Cramping Loss of Appetite Nausea Diarrhea Vomiting EG/EoD patients (n=65) MGID Patients (n=7)
Slide 30: 64% Improvement in Total Symptom Score
64% Improvement in Total Symptom Score Mean % Change from BL Mean % Change from BL Antolimab 3.0 mg/kg Placebo MGID EG / EoD in ENIGMA PRO TSS-8: Change from Baseline Antolimab 3.0 mg/kg
Slide 31: Improvement Across All Symptoms Measured
Improvement Across All Symptoms Measured MGID: PRO Symptom Score Antolimab (n=7) Median Score -69% -78% -100% -90% -91% -57% -91% -85% Baseline End of Tx
Slide 32: MGID: Histologic Results
MGID: Histologic Results Median Eosinophils Cells Baseline Week 22 Median Mast Cells Baseline Week 22 -100% GI Eosinophils GI Mast Cells -18%
Slide 33: MGID: Safety Summary
MGID: Safety Summary Generally well tolerated Most common AE was infusion related reactions (IRR), all of which were mild No drug-related SAEs
Slide 34: EGID & MGID Prevalence Study
EGID & MGID Prevalence Study
Slide 35: EGID & MGID Prevalence Study
EGID & MGID Prevalence Study Study Design Multi-center study to assess prevalence of EGIDs and MGID in patients with chronic functional GI symptoms with or without diagnosis of Irritable Bowel Syndrome (IBS), Functional Dyspepsia (FD), or Chronic Gastritis Biopsies from >200 adult patients with acti
Slide 36: Summary
Summary Recently initiated Phase 3 EG/EoD and Phase 2/3 EoE studies First group dosed in subcutaneous healthy volunteer study Antolimab improves symptoms in patients with chronic GI symptoms and elevated mast cells (MGIDs) EGID & MGID prevalence study in patients with chronic functional GI disease i
Slide 37: Corporate Updates
Corporate Updates
Slide 38: Strong Balance Sheet and Significant IP Protection
Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of Dec 31, 2019 $495.9M Q4 2019 Operating Expenses $26.9M Antolimab US patents first to expire 2035 Lonza currently manufactures antolimab
Slide 39: Anticipated Near-term Milestones
Anticipated Near-term Milestones H2’20 EGID & MGID Prevalence Study Results H2’21 Phase 2/3 EoE Results* H2’20 Phase 1 Data For Subcutaneous Antolimab Q2’20 Phase 2 Extension Data in EG and/or EoD H2’21 Phase 3 EG and/or EoD Results* *Estimates subject to delay due to coronavirus
Slide 40: Thank you, Q&A
Thank you Q&A